Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
3
institutions
Market cap
$138.9B
708M shares
52-week range
$160.93 – $242.80
39% from low
Sector
INDUSTRIAL INSTRUMENTS FOR MEASUREMENT, DISPLAY, AND CONTROL
Exchange
NYSE
CS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $17.05B | $17.91B | $22.28B | $29.45B | $26.64B | $23.89B | $23.88B | $24.57B |
| Cost of revenue | $7.54B | $7.93B | $9.81B | $11.50B | $10.46B | $9.86B | $9.67B | $9.60B |
| Gross profit | $9.51B | $9.98B | $12.47B | $17.95B | $16.19B | $14.03B | $14.21B | $14.97B |
| Gross margin | 55.8% | 55.7% | 56.0% | 61.0% | 60.8% | 58.7% | 59.5% | 60.9% |
| R&D | $1.06B | $1.13B | $1.35B | $1.74B | $1.53B | $1.50B | $1.58B | $1.60B |
| Operating income | $3.07B | $3.36B | $4.31B | $8.05B | $7.54B | $5.28B | $5.18B | $5.14B |
| EBITDA | $4.28B | $4.60B | $6.54B | $10.01B | $9.48B | $7.50B | $7.28B | $6.95B |
| Net income | $2.65B | $2.56B | $3.65B | $6.43B | $7.21B | $4.76B | $3.90B | $3.61B |
| Net margin | 15.5% | 14.3% | 16.4% | 21.8% | 27.1% | 19.9% | 16.3% | 14.7% |
| EPS (diluted) | 3.73 | 3.43 | 4.89 | 8.61 | 9.64 | 6.38 | 5.29 | 5.04 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $25.5B | $8.44 | $8.38–$8.58 | 5 |
| 2027 | $27.1B | $9.11 | $8.95–$9.39 | 6 |
| 2028 | $28.9B | $9.96 | $8.84–$11.42 | 3 |
| 2029 | $30.8B | $10.83 | $10.49–$11.23 | 1 |
Forward consensus · source: Financial Modeling Prep
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life sciences and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
www.danaher.comNo one on the platform currently holds DHR.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 678,808 | $128.7M |
| Third Point LLCas of 2026-03-31 | 525,000 | $99.5M |
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-06-26 | $0.4000 | 2026-07-31 |
| 2026-03-27 | $0.4000 | 2026-04-24 |
| 2025-12-26 | $0.3200 | 2026-01-30 |
| 2025-09-26 | $0.3200 | 2025-10-31 |
| 2025-06-27 | $0.3200 | 2025-07-25 |
| 2025-03-28 | $0.3200 | 2025-04-25 |
| 2024-12-27 | $0.2700 | 2025-01-31 |
| 2024-09-27 | $0.2700 | 2024-10-25 |
| 2024-06-28 | $0.2700 | 2024-07-26 |
| 2024-03-27 | $0.2700 | 2024-04-26 |
No one on the platform has traded DHR yet.
| 25,349 |
| $4.8M |
| 2023-12-28 |
| $0.2400 |
| 2024-01-26 |
| 2023-10-11 | $0.2700 | 2023-10-27 |
| Execution date | Ratio |
|---|---|
| 2016-07-05 | 1319-for-1000 |
| 2010-06-14 | 2-for-1 |
| 2004-05-21 | 2-for-1 |
Trading at 37.4× earnings vs its 37.6× historical median P/E.
Fair value ≈ $193.64 · price $192.78 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
Expectations were probably too high. Market is forcing a reset and patient capital isn't running to the rescue just yet. Chasing the bounce here feels risky when the macro money is sitting on its hands. Still watching $DHR.
View on StockTwits ↗Rotation is doing exactly what it usually does late-cycle- money stops chasing momentum and starts hiding in defensives with visible cash flows. This week the tape flipped hard: $ABBV +17% | pharma leadership catching bid on defensive + yield rotation $MRK +13% | large-cap healthcare strength as risk appetite fades $JNJ +12% | classic safety trade back in favor $DHR +11% | life sciences tools seeing steady institutional demand $LLY +10% | still strong structurally, but now part of broader defensive bid Meanwhile semis are cooling as AI beta unwinds from stretched positioning. This isn’t “AI is dead” pricing. It’s capital rotating from narrative to stability. When healthcare leads and semis lag, the market is telling you one thing: risk is being reduced, not added
View on StockTwits ↗This week’s tape rotation is pretty clear - AI and semis took a breather, while defensives quietly led. 1-week returns: $ABBV +17% (AbbVie) $MRK +13% (Merck) $JNJ +12% (Johnson & Johnson) $DHR +11% (Danaher) $LLY +10% (Eli Lilly) What stands out isn’t just performance, but leadership shifting into healthcare while high-beta growth cooled off. This kind of rotation usually says more about positioning stress than any single macro headline - when crowded trades unwind, capital doesn’t disappear, it just moves.
View on StockTwits ↗Imagine buying $DHR at its peak, only to watch it crash like this and then finding out there’s a way to get some money back. To all $DHR investors out there, we’ve got some important news: a $172.5 million investor settlement is now open for claims from shareholders who purchased shares between 2022 and 2023. The deadline is in three months, you can check if you’re eligible and claim your share: https://11th.com/cases/danaher-investor-settlement
View on StockTwits ↗TODAY'S BIGGEST BETS $NVDA $MU $DHR The 4 largest options bets on index names today: Those MU puts down $3,000,000.00 Crazy bet on basically weeklies 1. $18.06M hit the Jan 21 '28 $200 NVDA puts at 9:29 AM ET while NVDA was near $194.47 — ~4,548 contracts at $39.71, day volume 4,660 vs OI 21,351, latest option mark $38.50 (-3% vs entry). 2. $7.42M hit the Jun 17 '27 $205 NVDA calls (sweep) at 10:08 AM ET while NVDA was near $195.97 — ~2,219 contracts at $33.45, day volume 2,281 vs OI 17,218, latest option mark $32.50 (-3% vs entry). 3. $6.45M hit the Jul 2 '26 $1150 MU puts (sweep, mostly new positioning) at 9:06 AM ET while MU was near $1147.37 — ~949 contracts at $68.00, day volume 1,266 vs OI 305, latest option mark $40.00 (-41% vs entry). 4. $6.23M hit the Sep 18 '26 $185 DHR calls at 9:16 AM ET while DHR was near $196.06 — ~3,250 contracts at $19.17, day volume 3,251 vs OI 3,796, latest option mark $18.50 (-3% vs entry).
View on StockTwits ↗https://youtube.com/watch?v=uaDtxF-IKqY&is=alcSIj3Ce5ewCDx_ $jpm $dhr $mrk
View on StockTwits ↗$DHR ripped 5.7% to around $189, an outsized move at nearly 3x its typical daily range. After a steady drawdown, this looks more like volatility expansion than a clean trend reversal. Still sitting ~22% below its 52-week high, so overhead supply is very real. The key is whether buyers can build acceptance here or if this fades into another relief bounce.
View on StockTwits ↗$DHR continues to transform its portfolio, moving aggressively toward high-margin diagnostics and life science tools. With the Masimo acquisition slated for 2H 2026 and margins expanding toward 23%, the operational leverage is clear. However, the market is cautious about the "strategic fit" of recent M&A. Patience is the edge while the bioprocessing cycle converts into sustained revenue growth. 💰 #hovdid 🐂 Bull Level: Sustain momentum above $180.00 to maintain the recovery trend. 🐻 Bear Level: Watching $175.00 as the primary pivot—if it fails, the technical consolidation could deepen toward the $160 support zone. #DHR #SmartMoney #Healthcare #Trading #hovdid
View on StockTwits ↗$DHR Current Stock Price: $188.95 Contracts to trade: $190.0 DHR Jun 26 2026 Call Entry: $0.90 Exit: $1.32 ROI: 47% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
View on StockTwits ↗$DHR That’s It! DHR exec mgmt you are formally being put on a PIP!!
View on StockTwits ↗$DHR Share Price: $177.16 Contract Selected: Jul 17, 2026 $175 Calls Buy Zone: $6.20 – $7.65 Target Zone: $10.59 – $12.94 Potential Upside: 61% ROI Time to Expiration: 24 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗$DHR large August call buyer into the close. Almost $2M in premium. Recent July spread opened as well.
View on StockTwits ↗Did you own $DHR shares? A $172 million investor settlement has been reached. If you owned $DHR between January 27, 2022, and October 23, 2023, you may want to check whether you're eligible: https://11th.com/cases/danaher-investor-settlement
View on StockTwits ↗$DHR completes acquisition of $MASI https://www.prnewswire.com/news-releases/danaher-completes-acquisition-of-masimo-corporation-302796748.html MASI shareholders to receive $180 per share.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.